Clinical Trial: NRG EAY191-N5

NRG EAY191-N5

Status: Open

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
(See required screening study ECOG-ACRIN EAY191)